Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Institutes of Health Clinical Center (CC)
Study ID
NCT00020501
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FOLFIRI regimen — DRUG
  • floxuridine — DRUG
  • fluorouracil — DRUG
  • irinotecan hydrochloride — DRUG
  • leucovorin calcium — DRUG
  • melphalan — DRUG
  • hyperthermia treatment — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known which chemotherapy regimen is most effective for colorectal cancer that has spread to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without isolated hepatic perfusion with melphalan in treating patients who have colorectal cancer that has spread to the liver.

Key Dates

Start date
Mar 31, 2001
Status verified
Mar 2012
Completion
Jan 31, 2005

Study Design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Studies SupportBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support· Bethesda, MD

Related Studies